Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer

Ami N. Shah*, Lisa Flaum, Irene Helenowski, Cesar A. Santa-Maria, Sarika Jain, Alfred Rademaker, Valerie Nelson, Dean Tsarwhas, Massimo Cristofanilli, William Gradishar

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry